Seven Eight Capital LP Has $2.34 Million Position in Zoetis Inc (ZTS)

Share on StockTwits

Seven Eight Capital LP increased its position in shares of Zoetis Inc (NYSE:ZTS) by 108.3% in the third quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund owned 25,579 shares of the company’s stock after buying an additional 13,300 shares during the period. Seven Eight Capital LP’s holdings in Zoetis were worth $2,342,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also recently made changes to their positions in the stock. Polen Capital Management LLC raised its stake in Zoetis by 3.9% during the second quarter. Polen Capital Management LLC now owns 9,295,080 shares of the company’s stock worth $791,848,000 after buying an additional 351,447 shares during the last quarter. Brown Advisory Inc. raised its stake in Zoetis by 0.3% during the first quarter. Brown Advisory Inc. now owns 7,226,660 shares of the company’s stock worth $603,499,000 after buying an additional 19,546 shares during the last quarter. Wells Fargo & Company MN raised its stake in Zoetis by 9.1% during the second quarter. Wells Fargo & Company MN now owns 6,375,146 shares of the company’s stock worth $543,099,000 after buying an additional 529,666 shares during the last quarter. Janus Henderson Group PLC raised its stake in Zoetis by 22.3% during the second quarter. Janus Henderson Group PLC now owns 5,410,040 shares of the company’s stock worth $460,890,000 after buying an additional 985,586 shares during the last quarter. Finally, Bank of New York Mellon Corp raised its stake in Zoetis by 8.7% during the second quarter. Bank of New York Mellon Corp now owns 5,262,461 shares of the company’s stock worth $448,309,000 after buying an additional 422,856 shares during the last quarter. 89.79% of the stock is owned by institutional investors and hedge funds.

In other news, insider Kristin C. Peck sold 5,000 shares of the business’s stock in a transaction dated Wednesday, August 1st. The shares were sold at an average price of $86.22, for a total transaction of $431,100.00. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, insider Roxanne Lagano sold 2,000 shares of the business’s stock in a transaction dated Monday, October 1st. The stock was sold at an average price of $92.03, for a total transaction of $184,060.00. The disclosure for this sale can be found here. Over the last three months, insiders have sold 213,467 shares of company stock valued at $19,502,725. 0.35% of the stock is currently owned by insiders.

ZTS has been the subject of several research analyst reports. JPMorgan Chase & Co. raised shares of Zoetis from a “neutral” rating to an “overweight” rating and set a $100.00 price target for the company in a research note on Monday, October 15th. Cantor Fitzgerald reaffirmed a “buy” rating and issued a $98.00 price target on shares of Zoetis in a research note on Monday, October 1st. Stifel Nicolaus downgraded shares of Zoetis from a “buy” rating to a “hold” rating and set a $95.00 price target for the company. in a research note on Tuesday, August 21st. They noted that the move was a valuation call. Zacks Investment Research raised shares of Zoetis from a “hold” rating to a “buy” rating and set a $101.00 price target for the company in a research note on Monday, September 10th. Finally, Argus lifted their price target on shares of Zoetis from $90.00 to $103.00 and gave the company a “buy” rating in a research note on Tuesday, August 14th. Seven equities research analysts have rated the stock with a hold rating and thirteen have issued a buy rating to the company. Zoetis has a consensus rating of “Buy” and a consensus target price of $92.63.

NYSE:ZTS opened at $92.80 on Tuesday. The company has a quick ratio of 2.92, a current ratio of 4.38 and a debt-to-equity ratio of 2.50. The stock has a market cap of $44.07 billion, a PE ratio of 38.67, a price-to-earnings-growth ratio of 1.74 and a beta of 1.01. Zoetis Inc has a one year low of $63.03 and a one year high of $94.31.

Zoetis (NYSE:ZTS) last posted its earnings results on Thursday, August 2nd. The company reported $0.77 EPS for the quarter, topping the consensus estimate of $0.71 by $0.06. The company had revenue of $1.42 billion during the quarter, compared to the consensus estimate of $1.38 billion. Zoetis had a net margin of 19.95% and a return on equity of 72.30%. The firm’s revenue for the quarter was up 11.5% on a year-over-year basis. During the same period in the previous year, the firm posted $0.53 earnings per share. On average, equities analysts predict that Zoetis Inc will post 3.07 earnings per share for the current fiscal year.

The firm also recently announced a quarterly dividend, which will be paid on Monday, December 3rd. Stockholders of record on Tuesday, November 20th will be given a dividend of $0.126 per share. This represents a $0.50 annualized dividend and a dividend yield of 0.54%. The ex-dividend date of this dividend is Monday, November 19th. Zoetis’s payout ratio is presently 20.83%.

Zoetis Profile

Zoetis Inc discovers, develops, manufactures, and markets veterinary vaccines and medicines in the United States and internationally. It commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep; and companion animals comprising dogs, cats, and horses.

Recommended Story: Understanding Analyst Ratings

Institutional Ownership by Quarter for Zoetis (NYSE:ZTS)

Receive News & Ratings for Zoetis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zoetis and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply